GLOBAL-RAYTUR
11.5.2018 04:02:08 CEST | Business Wire | Press release
On May 9th , the mid-term conference of the World Ports Conference was held by International Association of Ports and Harbors (IAPH) in Baku, Azerbaijan. Over 300 ports and port-related companies and organizations worldwide participated in the Conference. As the host for World Ports Conference 2019 and an important foreign trade port of China, Guangzhou Port Authority extended its warm invitation to all guests.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180510006415/en/
To host World Ports Conference 2019 is a milestone for Guangzhou Port. It is also an important step to accelerate the construction and development of national central cities and shipping hubs and the forming of a new pattern of all-around opening up in China. Ms.Yuan stated that “the development of the port cannot be separated from the city. It is even more than just cooperation with the port sector. Instead, the projects should be the trigger activating trades, logistics, ports and other departments to jointly develop and standardize the ports.” She also mentioned that during 31st World Ports Conference in Guangzhou next year the host will launch the ‘Friend Circle’ Initiative for ports along ‘Belt and Road’ to promote trade facilitation and internationalization of Chinese standards.
This time Guangzhou Port Authority chose “Collaborate Now, Create Future” as the theme in its exhibition area, where fully demonstrated the port of Guangzhou as an international shipping hub which is always dedicated to improving modern shipping logistics services and building a smart green and safe port, as well as deepening the exchanges and cooperation internationally. Guangzhou Port Authority also signed a sister port cooperation agreement with Baku International Sea Trade Port, who becomes the 42nd sister port of Guangzhou. Thanks to the conferences of IAPH, Guangzhou Port now maintains friendly cooperation with over 100 countries and 400 ports worldwide.
Since the issuance of the "Three-Year Action Plan for the Construction of the Guangzhou International Shipping Center" in 2015, three years of hard work has led to a big leap in port production, the gathering and radiation power has expanded, new breakthroughs have been made in factor gathering, and key projects such as the Nansha International Cruise Terminal have kicked off. The construction will add new momentum to the gateway hub. China (Guangzhou) International Freight single window has become a leading and demonstrative example among its peers in China.
With the launch of the new 3-year Action Plan, the port of Guangzhou will use the port as a fulcrum to strengthen the connectivity with the regions and cities along the “Belt and Road” initiative, and rapidly enhance the internationalization process of Guangzhou Port. By strictly following the “Belt and Road” initiative and grasping the opportunities of the policy of building a powerful country with strong traffic, powerful oceans, as well as the Bay Area construction of Guangdong, Hong Kong, and Macao, multiple measures will be taken together to promote the construction of the Guangzhou International Shipping Center and jointly create a world-class shipping hub.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180510006415/en/
Contact:
Global Raytur (Beijing) Public Communication Co.,Ltd
Shirley
86
13720002197
wangyishan@globalraytur.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release
Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
